航锦科技(000818.SZ):董事长蔡卫东拟增持3000万元-5000万元股份
格隆汇2月3日丨航锦科技(000818.SZ)公布,2020年2月2日,公司收到公司董事长蔡卫东关于增持计划的书面说明。蔡卫东基于对公司未来发展前景的信心和对公司价值的认可,拟于2020年2月3月至8月3日期间(窗口期不交易),以自有或自筹资金,通过二级市场集中竞价交易方式增持公司股份,计划增增持金额为3000万元-5000万元。
蔡卫东目前直接持有公司股份220万股,占公司总股本的0.32%;通过杭州万珹投资合伙企业(有限合伙)间接持有公司股份779.7668万股,占公司总股本的1.13%。蔡卫东直接及间接合计持有公司999.7668万股,占公司总股本的1.45%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.